Oxford University begins first human trial of Bundibugyo Ebola vaccine

The University of Oxford began human trials of a vaccine targeting the Bundibugyo strain of Ebola on July 14, 2026. The early-stage study will enroll 50 healthy adults to assess the vaccine's safety and immune response.

Outbreak context The virus has spread across much of the Democratic Republic of Congo and parts of Uganda. Officials in the Democratic Republic of Congo said the disease had reached two new provinces. The outbreak has caused more than 700 deaths. The U.S. said it would block American citizens in the Democratic Republic of Congo from traveling back home until they have spent 21 days in a third country, leaving dozens stranded.

The spread has been aided by rampant misinformation and a major deficit in health supplies.

Vaccine details The vaccine uses the same chimpanzee adenovirus platform as the Oxford-AstraZeneca COVID-19 shot and was developed with funding from the Coalition for Epidemic Preparedness Innovations. The Serum Institute of India said it has already manufactured and stockpiled about 620,000 doses of the experimental shot in anticipation of later-stage trials and potential emergency use if it proves effective.

It supplied 4,000 doses for the phase-1 study. The trial is beginning 57 days after the World Health Organization declared the Ebola outbreak in the Democratic Republic of Congo and neighboring Uganda a public health emergency of international concern.

next steps There are no approved vaccines or specific treatments for the Bundibugyo virus. Existing licensed Ebola vaccines target the Zaire strain and are not approved against Bundibugyo. Even if the Bundibugyo vaccine succeeds, it is unlikely to alter the course of the current outbreak in the near term.

Early-stage clinical trials are not an immediate solution for communities facing the outbreak today, said Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention. A modeling study released ahead of peer review found that quickly identifying Ebola cases and tracing contacts would reduce deaths more than vaccinating only patients' contacts if the existing Ebola vaccine provides only limited protection against the Bundibugyo strain.